About Vero Biotech
Vero Biotech is a company based in Atlanta (United States) founded in 2017. Vero Biotech has raised $30 million across 2 funding rounds from investors including Runway Growth Capital and Petrichor. The company has 268 employees as of December 31, 2021. Vero Biotech offers products and services including GENOSYL Delivery System. Vero Biotech operates in a competitive market with competitors including Sysadvance, Absstem, Genrich Membranes, Phortman and Tgpoxygen, among others.
- Headquarter Atlanta, United States
- Employees 268 as on 31 Dec, 2021
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Vero Biotech Inc
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$30 M (USD)
in 2 rounds
-
Latest Funding Round
$30 M (USD), Series B
Jan 11, 2023
-
Investors
Runway Growth Capital
& 1 more
-
Employee Count
268
as on Dec 31, 2021
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Vero Biotech
Vero Biotech offers a comprehensive portfolio of products and services, including GENOSYL Delivery System.
Tankless system for on-demand nitric oxide in pulmonary treatment.
People of Vero Biotech
Unlock access to complete
Funding Insights of Vero Biotech
Vero Biotech has successfully raised a total of $30M across 2 strategic funding rounds. The most recent funding activity was a Series B round of $30 million completed in January 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Vero Biotech
Vero Biotech has secured backing from 2 investors, including venture fund investors. Prominent investors backing the company include Runway Growth Capital and Petrichor.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Petrichor is engaged in supporting healthcare innovation through investments.
|
Locked | Locked | Locked | |
|
Venture debt financing is provided to companies across multiple sectors.
|
Locked | Locked | Locked |
Investor details for Vero Biotech
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Vero Biotech
Investment portfolio details for Vero Biotech
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Vero Biotech
Detailed financials for Vero Biotech
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Vero Biotech Comparisons
Peer comparison for Vero Biotech
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Vero Biotech
Vero Biotech operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Sysadvance, Absstem, Genrich Membranes, Phortman and Tgpoxygen, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Developer of on-site gas generation and gas purifiers
|
|
| Locked | Locked | Locked |
Produces PSA generators for medical oxygen and industrial nitrogen supply services.
|
|
| Locked | Locked | Locked |
Developer of oxygen enrichment unit
|
|
| Locked | Locked | Locked |
Gas outlets for medical gas delivery
|
|
| Locked | Locked | Locked |
Medical gases delivery systems and vacuum services are supplied.
|
Detailed competitors of Vero Biotech
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Vero Biotech
Complete news archive for Vero Biotech
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Vero Biotech
Vero Biotech was founded in 2017 and raised its 1st funding round 4 years after it was founded.
Vero Biotech is headquartered in Atlanta, United States. It is registered at Atlanta, Georgia, United States.
Brent V Furse is the current CEO of Vero Biotech.
Vero Biotech is a funded company, having raised a total of $30M across 2 funding rounds to date.
As of Dec 31, 2021, the latest employee count at Vero Biotech is 268.
Vero Biotech was established in 2017 in Atlanta, United States, within the biotechnology sector. Inhaled nitric oxide delivery systems are developed by the company for cardiopulmonary applications. GeNOsyl is provided as a specialized system to address persistent pulmonary hypertension of the newborn (PPHN) accompanied by hypoxic respiratory failure. Operations focus on medical device innovation for neonatal care in the United States.
Vero Biotech's top competitors include Absstem, Genrich Membranes and Sysadvance.
Vero Biotech offers GENOSYL Delivery System.
Vero Biotech has 2 investors. Key investors include Runway Growth Capital, and Petrichor.